Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.04. | Stimcell Energetics Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
28.03. | Stimcell Energetics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.03. | StimCell Energetics Provides Sneak Peek at eBalance Redesign Progress and Announces Shares for Debt Transaction and the Engagement of Independent Investor Relations Consultant | 392 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 26, 2025 / StimCell Energetics Inc. (OTC PINK:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness... ► Artikel lesen | |
25.02. | StimCell Energetics Partners With ADM Tronics to Redesign eBalance Microcurrent Device for Home Use | 844 | ACCESS Newswire | Innovative Redesign Brings Smaller, Cost-Effective Unit with Advanced Diagnostics to Consumers VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / February 25, 2025 / StimCell Energetics Inc. (OTC PINK:STME)... ► Artikel lesen | |
STIMCELL ENERGETICS Aktie jetzt für 0€ handeln | |||||
30.01. | StimCell Energetics Launches Social Media Presence | 257 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / January 30, 2025 / StimCell Energetics Inc. (OTC PINK:STME) ("StimCell", or the "Company"), a biotech company targeting cellular energy to promote anti-aging, longevity... ► Artikel lesen | |
08.01. | StimCell Energetics Inc. Signs Marketing Agreement with Think Ink Marketing | 333 | ACCESS Newswire | VANCOUVER, BC / ACCESSWIRE / January 8, 2025 / StimCell Energetics Inc. (OTC PINK:STME) ("StimCell", or the "Company") a biotech company targeting cellular energy to promote anti-aging, longevity and... ► Artikel lesen | |
04.11.24 | Cell MedX Corp. Announces Major Corporate Updates and Rebranding to StimCell Energetics Inc. | 545 | ACCESS Newswire | VANCOUVER, BC / ACCESSWIRE / November 4, 2024 / StimCell Energetics Inc. (formerly "Cell MedX Corp.") (OTC PINK:CMXC) ("StimCell", or the "Company") a biotech company targeting cellular energy to promote... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,111 | +0,91 % | Sernova Corp.: Sernova Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investor Conference | ||
FAMICORD | 7,000 | +1,45 % | Bayer, BioNxt Solutions, FamiCord AG - Unentdeckte Perlen mit großer Wachstumsfantasie | Während Künstliche Intelligenz seit Monaten die Schlagzeilen dominiert und Tech-Aktien Rekordbewertungen erreichen, führt die Biotechbranche ein Schattendasein an den Börsen. Anleger meiden die oft... ► Artikel lesen | |
GERATHERM MEDICAL | 3,250 | +4,84 % | Geratherm Medical AG: Starkes Wachstum im ersten Halbjahr und operatives Break-even; KAUFEN bestätigt. | Geratherm verzeichnete im ersten Halbjahr 2025 ein starkes Wachstum: Die vergleichbaren Umsätze stiegen um 13,2 % gegenüber dem Vorjahr und sequenziell um 15,4 %. Getrieben wurde dieses Wachstum von... ► Artikel lesen | |
PLUS THERAPEUTICS | 0,487 | +1,37 % | Plus Therapeutics stock rating upgraded to Buy by D. Boral Capital | ||
MEDICLIN | 2,980 | -0,67 % | EQS-News: MEDICLIN AG: MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025
31.07.2025 / 13:13 CET/CEST
Für... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,690 | +0,44 % | Atossa Genetics stock rating reiterated by H.C. Wainwright on FDA meeting plans | ||
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting | -- Special Meeting to be held on September 26, 2025 --
SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc.... ► Artikel lesen | |
SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced | BOULDER, CO / ACCESS Newswire / August 26, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
VERU | 3,350 | -0,30 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
LIFEWARD | 0,550 | +2,52 % | Lifeward Ltd.: Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
LIGHT AI | 0,142 | -2,41 % | Light AI Announces Voting Results for Annual General Meeting | ||
MAVEN BRANDS | 0,001 | 0,00 % | Maven Brands Inc: Maven Brands to sell subdivided Lumby land for $3.5M | ||
EKSO BIONICS | 3,995 | -3,27 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Second Quarter 2025 Financial Results | SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
IMUNON | 4,900 | -1,21 % | Imunon, Inc.: IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement | LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 42,850 | +1,25 % | UBS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Sell' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für die Aktien von FMC von 43,50 auf 38 Euro gesenkt und die Papiere von "Neutral" auf "Sell" abgestuft. Analyst Graham Doyle... ► Artikel lesen |